Produk

Pabrik kita nyedhiyakake China Iminazole, Pyridine, Heterocyclics, Iguratimod, Apremilast, Bromhexine HCl, dll. Saben uwong ngerti kita amarga layanan sing apik, rega sing padha, lan produk kaliber dhuwur. Sampeyan olèh kanggo nyelehake pesenan.
View as  
 
CAS 169590-42-5

CAS 169590-42-5

CAS 169590-42-5 kanggo obat anti-inflamasi nonsteroid, kanggo obat osteoarthritis, obat arthritis rheumatoid, obat arthritis rheumatoid remaja.

Waca liyaneKirim Pitakonan
169590-42-5

169590-42-5

169590-42-5 kanggo obat anti-inflamasi nonsteroid, kanggo obat osteoarthritis, obat arthritis rheumatoid, obat arthritis rheumatoid remaja.

Waca liyaneKirim Pitakonan
Celecoxib API

Celecoxib API

Celecoxib API kanggo obat anti-inflamasi nonsteroid, kanggo obat osteoarthritis, obat arthritis rheumatoid, obat arthritis rheumatoid remaja.

Waca liyaneKirim Pitakonan
(3R,4R)-4-Metil-3-(metil-7H-pirolo[2,3-d]pirimidin-4-ylamino)-b-oxo-1-piperidinepropanenitrile: 2-Hydroxy-1,2,3- propanetrikarboksilat

(3R,4R)-4-Metil-3-(metil-7H-pirolo[2,3-d]pirimidin-4-ylamino)-b-oxo-1-piperidinepropanenitrile: 2-Hydroxy-1,2,3- propanetrikarboksilat

(3R,4R)-4-Metil-3-(metil-7H-pirolo[2,3-d]pirimidin-4-ylamino)-b-oxo-1-piperidinepropanenitrile: 2-Hydroxy-1,2,3- propanetikarboksilat kanggo obat arthritis rheumatoid, obat arthritis psoriatik, obat spondylitis ankylosing, obat arthritis idiopatik remaja kursus poliartikular, obat kolitis ulcerative.

Waca liyaneKirim Pitakonan
CAS NO.540737-29-9

CAS NO.540737-29-9

CAS NO.540737-29-9 kanggo obat arthritis rheumatoid, obat arthritis psoriatik, obat spondylitis ankylosing, obat arthritis idiopatik remaja polyarticular, obat kolitis ulcerative.

Waca liyaneKirim Pitakonan
CAS 540737-29-9

CAS 540737-29-9

CAS 540737-29-9 kanggo obat arthritis rheumatoid, obat arthritis psoriatik, obat spondylitis ankylosing, obat arthritis idiopatik remaja kursus poliartikular, obat kolitis ulcerative.

Waca liyaneKirim Pitakonan
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept